SEC Form 4
Charles River Laboratories International, Inc. (CRL) insider trading
In the 12 months to Oct 23, 2026, 7 CRL insiders reported open-market sales of $43.0M across 12 filings; one evp, corp strategy & develop bought $4.4K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $43.0M
- 12 filings · 7 insiders
- Open-market purchases
- $4.4K
- 1 filing · Joseph W. LaPlume, EVP, Corp Strategy & Develop
- Pre-arranged sales (10b5-1)
- 8 of 12
- $39.9M of $43.0M sold (93%)
Who traded CRL, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
CRL daily close from Oct 23, 2025 to Oct 23, 2026, between $149.93 and $345.37, last $345.37. 12 sale and 1 purchase filings by 7 insiders, marked at their filing dates. James C. Foster, Director: sold $34.8M across 3 filings, first filed Jul 1, 2026, last Aug 27, 2026. Shannon M. Parisotto, CEVP, Disc & Safety Assessment: sold $3.3M across 4 filings, first filed Aug 6, 2026, last Oct 7, 2026. Birgit Girshick, Chief Executive Officer: sold $1.8M across 1 filing, first filed Aug 13, 2026, last Aug 13, 2026. Michael Gunnar Knell, SVP, Finance and CAO: sold $1.7M across 1 filing, first filed Aug 10, 2026, last Aug 10, 2026. Victoria L. Creamer, EVP & Chief People Officer: sold $1.1M across 1 filing, first filed Aug 10, 2026, last Aug 10, 2026. Nancy C. Andrews, Director: sold $163.4K across 1 filing, first filed Aug 20, 2026, last Aug 20, 2026. Joseph W. LaPlume, EVP, Corp Strategy & Develop: sold $65.5K and bought $4.4K across 2 filings, first filed Jan 20, 2026, last Mar 4, 2026.
Largest mark · tap a row for others
James C. Foster · Director
Sale $16,875,000
75,000 shares at $225.00 avg
Filed Jul 1, 2026 · traded Jun 29
Pre-arranged (10b5-1) · close on filing date $229.09
James C. Foster · Director
Director
$34.8M soldShannon M. Parisotto · CEVP, Disc & Safety Assessment
CEVP, Disc & Safety Assessment
$3.3M soldBirgit Girshick · Chief Executive Officer
Chief Executive Officer
$1.8M soldMichael Gunnar Knell · SVP, Finance and CAO
SVP, Finance and CAO
$1.7M soldVictoria L. Creamer · EVP & Chief People Officer
EVP & Chief People Officer
$1.1M soldNancy C. Andrews · Director
Director
$163.4K soldJoseph W. LaPlume · EVP, Corp Strategy & Develop
EVP, Corp Strategy & Develop
$65.5K sold$4.4K boughtHas Charles River Laboratories International, Inc.'s CEO sold stock?
Yes. Birgit Girshick (CEO) sold 6,500 shares ($1.8M) in Aug 2026, all under a pre-arranged 10b5-1 plan. James C. Foster (CEO) made no open-market sales filed as CEO in the last 12 months.
Open-market trades
13 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| James C. Foster | Director | $34.8M | — | 3 | 100% of sales | |
| Shannon M. Parisotto | CEVP, Disc & Safety Assessment | $3.3M | — | 4 | 100% of sales | |
| Birgit Girshick | Chief Executive Officer | $1.8M | — | 1 | 100% of sales | |
| Michael Gunnar Knell | SVP, Finance and CAO | $1.7M | — | 1 | — | |
| Victoria L. Creamer | EVP & Chief People Officer | $1.1M | — | 1 | — | |
| Nancy C. Andrews | Director | $163.4K | — | 1 | — | |
| Joseph W. LaPlume | EVP, Corp Strategy & Develop | $65.5K | $4.4K | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Shannon M. Parisotto CEVP, Disc & Safety Assessment | SalePre-arranged (10b5-1) | 981 | $308.44 | $302.6K | 4,807 | |
traded | James C. Foster Director | SalePre-arranged (10b5-1) | 33,561 | $300.00 | $10.1M | 31,596 | |
traded | Nancy C. Andrews Director | Sale | 573 | $285.24 | $163.4K | 1,438 | |
traded | Shannon M. Parisotto CEVP, Disc & Safety Assessment | SalePre-arranged (10b5-1) | 2,039 | $294.12 | $599.7K | 4,807 | |
traded | Shannon M. Parisotto CEVP, Disc & Safety Assessment | SalePre-arranged (10b5-1) | 3,714 | $279.66 | $1.0M | 4,807 | |
traded | Birgit Girshick Chief Executive Officer | SalePre-arranged (10b5-1) | 6,500 | $279.90 | $1.8M | 36,013 | |
traded | James C. Foster Director | SalePre-arranged (10b5-1) | 28,733 | $275.00 | $7.9M | 31,596 | |
traded | Victoria L. Creamer EVP & Chief People Officer | Sale | 4,179 | $259.16 | $1.1M | 30,051 | |
traded | Michael Gunnar Knell SVP, Finance and CAO | Sale | 6,645 | $260.38 | $1.7M | 11,852 | |
traded | Shannon M. Parisotto CEVP, Disc & Safety Assessment | SalePre-arranged (10b5-1) | 5,046 | $263.00 | $1.3M | 4,807 | |
traded | James C. Foster Director | SalePre-arranged (10b5-1) | 75,000 | $225.00 | $16.9M | 31,596 | |
traded | Joseph W. LaPlume EVP, Corp Strategy & Develop | Purchase | 25 | $174.54 | $4.4K | 27,448 | |
traded | Joseph W. LaPlume EVP, Corp Strategy & Develop | Sale | 400 | $163.72 | $65.5K | 23,716 |
GET /stocks/filings/vX/form-4?tickers=CRL&filing_date.gte=2025-10-23&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"CRL"
],
"issuer_cik": "0001100682",
"owner_cik": "0001952784",
"accession_number": "0001952784-26-000003",
"form_type": "4",
"filing_date": "2026-10-07",
"period_of_report": "2026-10-05",
"issuer_name": "CHARLES RIVER LABORATORIES INTERNATIONAL, INC.",
"issuer_trading_symbol": "CRL",
"owner_name": "Parisotto Shannon M",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "CEVP, Disc & Safety Assessment",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-05",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 981,
"transaction_price_per_share": 308.44,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 4807,
"transaction_value": 302579.64,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was adopted on March 4, 2026."
}
]
},
{
"tickers": [
"CRL"
],
"issuer_cik": "0001100682",
"owner_cik": "0001141722",
"accession_number": "0001100682-26-000140",
"form_type": "4",
"filing_date": "2026-08-27",
"period_of_report": "2026-08-25",
"issuer_name": "CHARLES RIVER LABORATORIES INTERNATIONAL, INC.",
"issuer_trading_symbol": "CRL",
"owner_name": "FOSTER JAMES C",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-25",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 33561,
"transaction_price_per_share": 300,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 31596,
"transaction_value": 10068300,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 95 records
- Option exercises12 records
- Tax withholding32 records
- Grants and awards33 records
- Gifts17 records
- Employee stock purchase plan1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for CRL every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.